1 / 42

Pneumonia

Pneumonia. Definitions. New Pulmonary infiltrate that resembles bacterial pneumonia on CXR Hospital acquired Pneumonia - > 48 hrs after admission Ventilator Associated Pneumonia - > 48 hrs after Intubation

aurora
Download Presentation

Pneumonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pneumonia

  2. Definitions • New Pulmonary infiltrate that resembles bacterial pneumonia on CXR • Hospital acquired Pneumonia - > 48 hrs after admission • Ventilator Associated Pneumonia - > 48 hrs after Intubation • Health-care Associated Pneumonia – - previous hospitalization within 30 days - IV antibiotics, HD, within 30 days - transferred from another health care facility. - Will have to be stratified

  3. USA dataKollef et al Chest 2005;128:3854-3862

  4. Pathogenesis • Colonization of oropharynx • Aspiration of oropharyngeal secretions into lower respiratory tract • Compromise of the normal host defense mechanisms (ETT)

  5. CRB-65 • C – confusion • R – respiration rate >30/min • B – blood pressure MAP < 60 • 65 – age > 65

  6. Diagnosis • Clinical Features – fever, leucocytosis, purulent sputum, • CXR – pneumonia only 1/3rd of all ICU CXR infiltrates • 40% pulmonary infiltrates missed in CXR • 25% infiltrates persist after 4 weeks • Tracheobronchitis – fever & purulent sputum (CDC) • 50% of ARDS will develop Pneumonia

  7. Diagnosis – Tracheal Aspirates • Neg culture excludes pneumonia but +ve culture cannot be used to confirm it • Microscopic analysis – presence of macrophage & >25 neutrophils/hpf, epithelial cells <25/hpf • Quantitative culture – collect 1 ml in sterile trap without saline. • TA 105(75%), BAL 104(82%), PSB 103(90%) • BAL – 3% intracellular organisms

  8. A Randomized Trial of Diagnostic Techniques for Ventilator-Associated PneumoniaThe Canadian Critical Care Trials Group • In conclusion, we found that endotracheal aspiration with nonquantitative culture of the aspirate to diagnose ventilator-associated pneumonia is associated with clinical outcomes and antibiotic use similar to those that are associated with bronchoalveolar lavage and quantitative culture of the bronchoalveolar-lavage fluid NEJM December 21, 2006,355:2619-2630

  9. Microbiology of VAP • Early onset VAP • MSSA • Strep pneumoniae • H.Influenzae • Non resistant GNEB

  10. Microbiology of VAP • Late Onset VAP • Resistant GNEB • MRSA • Pseudomonas • Acinetobacter

  11. Choice of Antibiotics • Antimicrobial spectrum • Local Microbiology • Effective dose • Pharmacokinetics • Adverse effects • Cost • Availability

  12. HAP treatment recommendations was published in 2008 for Asian Countries by Asian HAP Working Group

  13. Initial Approach to Empirical Therapy HAP or VAP Suspected Evaluation • Risk Factors for MDR pathogen • Time of onset (early or late ) • Local microbiologic data and resistance pattern • Patient status • LRT sample Gram Stain • Allergy to medication • Underlying co-morbidities • Formulary restrictions • Cost Select Empirical Antibiotic therapy Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  14. Initial Empiric Antibiotic treatment for early onset HAP (Table I) *Antibiotic options should depend on local epedimiology of etiologic pathogens. $ The frequency of macrolide-resistant S. pneum and MDR S pneum is increasing; levofloxacin or moxifloxacin ae preferred to ciprofloxacin and the role of other new quinolones has not been established. Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  15. Initial Empiric Antibiotic treatment for late onset HAP (Table II) *if an ESBL strain such as K. pneum or an Acinetobacter sp. Is suspected the a carpenem is a reliable choice. If L. pneumophilia is suspected then the combination antibiotic regimen should include a macrolide (eg. Azithromycin) or a fluoroquinolone (eg. Ciprofloxacin or levofloxacin) should be used rather than an aminoglycoside. $ If MRSA risk factors are presenr or there is a high incidence locally. Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  16. Initial Empiric Antibiotic treatment for early onset VAP (Table III) Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  17. Initial Empiric Antibiotic treatment for late onset HAP (Table IV) Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  18. Treatment Recommendations for MDR pathogens

  19. MRSA • First line treatment : Teicoplanin or Vancomycin. • Teicoplanin as compared to Vancomycin has fewer side effects and does not require serum monitoring levels. • Linezolid to be reserved as second tier agent. Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  20. P. Aeruginosa • First line : Piperacillin/ tazobactum or carbapenems +/- aminoglycosides or fluoroqinolone • Fluoroqinolones offer theoretical advantage of improved bioavailability in respiratory tract. • Ciprofloxacin or LevofloxacinFluoroqinolones preferred in combination therapy • In unresponsive patients Polymyxin B or Colistin in combination with fluoroqinolone Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  21. Acinetobacter sp. • First Line: Cefoperazone/ sulbactam and/or tigecycline • Sulbactam an enzyme inhibitor has direct activity against Acinetobacter. • In unresponsive patients : Polymyxin B or Colistin Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  22. Antibiotic regimens against specific antibiotic – resistant pathogens Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  23. Duration of Treatment • Asian HAP Working Group recommends the initial empirical antibiotic treatment should continue for 7 to 14 days. • If MDR pathogen is identified then the treatment may be continued for up to 14 days. • Patient response should be evaluated frequently with consideration given to de-escalating therapy when appropriate. Song JH and Asian HAP Working Group, Am J of Inf Control; vol 36; issue 4 May 2008; S83-S92

  24. Microorganism Profile – Ventilator Associated Pneumonia (VAP)Updated on a quarterly basisKalinga Hospital , Mixed ICU

  25. Device Associated Infection Rates.Ventilator Associated Pneumonia per 1000 Device Days.Kalinga Hospital , Mixed ICU

  26. Extra Length of Stay Updated on a quarterly basisKalinga Hospital , Mixed ICU References:HAI: Health Care Associated Infection; CLABSI: Central Line Associated Blood Stream Infection; VAP: Ventilator Asscciated Pneumonia; CAUTI: Catheter Associated Urinary Tract Infection.

  27. Percentage of Deaths by HAI Updated on a Quarterly Basis Kalinga Hospital , Mixed ICU References:HAI: Health Care Associated Infection; CLABSI: Central Line Associated Blood Stream Infection; VAP: Ventilator Asscciated Pneumonia; CAUTI: Catheter Associated Urinary Tract Infection.

  28. CAP-128HCAP-7VAP-35(5 outside)

  29. Nosocomial Pneumonia KHL - 2006 • VAP (ICU acquired) - 9 – Pseudomonas - 5 - Klebsiella - 1 - MSSA - 1 • VAP (other hospital) – 1 • HAP (Aspiration Pneumonia) – 8 - Klebsiella – 5

  30. KHL-Tracheal Aspirates ICU Jun-Sep 07 • Acinetobacter – 12 • Pseudomonas – 9 • Klebsiella – 6 • E. coli – 2 • Enterobacter – 2 • Proteas – 1 • Providencia – 1 • MRSA – 6 • MSSA – 2 • Non H Streptococcus - 1

  31. KHL – Tracheal AspiratesSensitivity Jun-Sep 07 • Ceftazidime – 23% • Amikacin – 23% • Cefoperazone+sulbactum – 56% • Levofloxacin – 19% • Piperacillin+tazobactum – 37% • Meropenem – 53% • Imipenem – 76%

  32. Resolution • CRP – follow up after 72 hours. If fall in CRP is > 50% then your antibiotic is working

  33. Prevention of VAP • Handwashing • Raising the head of the bed to at least 30 degrees above horizontal • Guidelines for oral care, • Aspiration of subglottic secretions,

  34. Ventilator Bundles • Elevation of head end of bed • Daily sedation vacations & assessment for extubation • Peptic ulcer disease prophylaxis • DVT prophylaxis

  35. Saline installation before tracheal suctioning decreases the incidence of ventilator-associated pneumonia Caruso P, Demarzo SE, Ruiz SAL, Denari S, Deheinzelin D. .ATS 2006 International Conference; May 19-24, 2006; • The incidence of VAP was significantly less in the arm receiving saline. Only 10.7% of these patients suffered VAP compared with 23.5% of those in the control group • Routine use of saline prior to suctioning, as is the standard practice in US ICUs, helps to prevent VAP without exposing the patient to any evident risk.

More Related